At week 16, the primary end point of the trial, all patients were crossed over to open-label infliximab therapy through 50 weeks
However, forcing strict compliance can lead to treatment dropout
This is because public demand is high, online promotion is intense and unauthorised sellers can exploit search traffic
Participants, who administered Mounjaro, experienced an impressive average reduction in body weight of up to 21%
Emerging research is exploring whether intestinal permeability could also contribute to: Autoimmune disease (type 1 diabetes, rheumatoid arthritis) Chronic inflammation Even long COVID, MIS-C, and post-viral syndromes And yes in this letter, were going to touch on all of it
[DOI] [PubMed] [Google Scholar] 116.Manoharan M, Schwille PO